Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 5/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.51 |
| ▸ | HTR2B | P41595 | 3/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MGLL | Q99685 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | PRSS12 | P56730 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1593625 | 0.87 | CYP2C9 (0.55) | CYP2C9CYP2C19MAPK14HTR2BPKM | |
| SCHEMBL12589837 | 0.86 | ALDH1A1 (0.41) | MAPK14PKMSMN1; SMN2MEN1KMT2A | |
| SCHEMBL12589842 | 0.85 | SCD5 (0.46) | PKMSMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL12589838 | 0.83 | MAPK14 (0.49) | MAPK14PKMSMN1; SMN2ALDH1A1 | |
| SCHEMBL12589839 | 0.81 | ALDH1A1 (0.44) | MAPK14PKMSMN1; SMN2ALDH1A1 | |
| SCHEMBL12589844 | 0.80 | L3MBTL3 (0.47) | MAPK14ALDH1A1 | |
| SCHEMBL12589845 | 0.80 | ALDH1A1 (0.40) | MAPK14PKMSMN1; SMN2ALDH1A1 | |
| SCHEMBL17624645 | 0.79 | MAPT (0.47) | MAPK14PKMSMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL19396257 | 0.79 | L3MBTL3 (0.62) | ALDH1A1 | |
| SCHEMBL12589840 | 0.78 | CYP46A1 (0.47) | PKMCYP46A1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170273968-A1 | MAO-B INHIBITORS AND REHABILITATION | DART NEUROSCIENCE, LLC | 2017-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170273968-A1 | MAO-B INHIBITORS AND REHABILITATION | MAOB, MAOA, HTR2B | CYP2C9 587/4885CYP2C19 194/4885MAPK14 1743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.